Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025. In addition, the company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding. Ryvu’s…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.